Vaxart, Inc.
VXRT
Rank in Stocks
#20203
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Share Price
$0.3661
Last synced: 2026-11-09
Market Cap
$88.90M
Change (1 day)
-1.05%
Change (1 year)
-1.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vaxart, Inc. (VXRT)
Category
Healthcare
EPS for Vaxart, Inc. (VXRT)
EPS as of September 2026 TTM: $0.12
According to Vaxart, Inc.'s latest financial reports, its current EPS (TTM) is $0.12. At the end of 2025 the company had an EPS of $0.07, an increase over its 2024 EPS of $-0.14.
EPS history for Vaxart, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.12 | 71.43% |
| 2025 | $0.07 | -150.00% |
| 2024 | $-0.14 | -17.65% |
| 2023 | $-0.17 | -22.73% |
| 2022 | $-0.22 | 57.14% |
| 2021 | $-0.14 | 111.80% |
| 2020 | $-0.07 | -23.14% |
| 2019 | $-0.09 | -69.82% |
| 2018 | $-0.29 | -13.37% |
| 2017 | $-0.33 | -54.50% |
| 2016 | $-0.72 | 21.72% |
| 2015 | $-0.59 | 53.89% |
| 2014 | $-0.39 | 11.24% |
| 2013 | $-0.35 | -50.85% |
| 2011 | $-0.71 | -634.85% |
| 2010 | $0.13 | -105.41% |
| 2009 | $-2.44 | 2.39% |
| 2008 | $-2.38 | -146.31% |
| 2007 | $5.15 | -180.97% |
| 2006 | $-6.36 | -55.11% |
| 2005 | $-14.16 | 149.51% |
| 2004 | $-5.68 | 514.29% |
| 2003 | $-0.92 | -450.00% |
| 2002 | $0.26 | -98.55% |
| 2001 | $18.22 | 2,200.00% |
| 2000 | $0.79 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 12,950.00% |
US
|
|
| $-7.07 | -5,991.67% |
US
|
|
| $-5.29 | -4,508.33% |
AU
|
|
| $12.88 | 10,633.42% |
BE
|
|
| $21.56 | 17,866.67% |
NL
|
Questions about Vaxart, Inc.'s earnings per share (EPS)
What is Vaxart, Inc.'s earnings per share (EPS)?
Vaxart, Inc.'s earnings per share (EPS) over the last twelve months is $0.12, as of Sep 2026.
What was Vaxart, Inc.'s earnings per share (EPS) in 2025?
In 2025, Vaxart, Inc.'s earnings per share (EPS) was $0.07, compared with $-0.14 in 2024.
How has Vaxart, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Vaxart, Inc.'s earnings per share (EPS) was highest in 2025 ($0.07) and lowest in 2022 ($-0.22).
How does Vaxart, Inc.'s earnings per share (EPS) compare with similar companies?
Vaxart, Inc.'s earnings per share (EPS) ($0.12) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.